- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Survey shows why patients see urologists
During the year ending September 2000, urologists wrote 25.3 million retail prescriptions, 5% more than in the previous 12-month period, according to Newtown, PA-based Scott-Levin's Source™ Prescription Audit.
During the year ending September 2000, urologists wrote 25.3 million retail prescriptions, 5% more than in the previous 12-month period, according to Newtown, PA-based Scott-Levin's Source⢠Prescription Audit.
The top five therapeutic classes prescribed by these specialists were drugs for benign prostate disorders (10.6%), drugs for sexual function disorders (10.4%), urinary tract antispasmodics (10%), quinolone antibiotics (9.2%) and alpha-blockers (8.5%).
Urologists received nearly 30 million visits from patients during the year ending September 2000, 2% fewer than in the prior 12-month period, reports Scott-Levin's Physician Drug & Diagnosis Audit. The top three reasons for these visits were prostate hyperplasia (15%), prostate cancer (11%) and disorders of the penis (6%).
Prescriptions written by urologists generated nearly $1.4 billion in retail sales during the year ending September 2000, a 12% increase from the previous 12-month span, according to the audit. The top five companies benefiting from urologists' prescriptions were New York-based Pfizer Inc. ($227 million); Pharmacia Corp., Peapack, NJ ($121 million); AstraZeneca, Wilmington, DE ($112 million); Bayer Corp., West Haven, CT ($112 million); and Boehringer Ingelheim Corp., Ridgefield, CT ($102 million).
Pharmaceutical sales representatives made 800,000 details to urologists in the year ending September 2000, reports Scott-Levin's Personal Selling Audit/Hospital Personal Selling Audit. Reps most often called on urologists to promote Viagra® (sildenafil citrate) (12% of the total), Detrol⢠(tolterodine tartrate tablets) (11% of the total), Cipro® (ciprofloxacin) (8% of the total), Levaquin⢠(levofloxacin tablets) (7% of the total) and Ditropan® XL (oxybutynin chloride) (7% of the total).
During the same time period, Scott-Levin's Physician Meeting & Event Audit shows that urologists attended nearly 5,600 events held by pharmaceutical companies; Viagra (11% of events), Detrol (10% of events) and Proscar® (finasteride) (5% of events) were the top event topics. PR
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
